{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:30:14Z","timestamp":1780367414472,"version":"3.54.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Treatment with renin\u2010angiotensin system (\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              ) inhibitors might restrain the structural\/electrical remodeling associated with atrial fibrillation (AF). Limited evidence exists regarding the potential benefits of\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition post\u2010acute myocardial infarction (AMI) in patients with AF. This study sought to assess the association between\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition and all\u2010cause mortality and new\u2010onset AF in patients with\/without congestive heart failure (\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              ) post\u2010AMI.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Patients hospitalized for AMI between 2006 and 2012 were identified in Swedish registries. Patients were stratified in 4 subgroups; patients with\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              and AF (n=11\u00a0489); patients with\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              without AF (n=31\u00a0676); patients with AF without\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              (n=10\u00a0066); and patients without both\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              and AF (n=59\u00a0417). Patients exposed to\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition were compared to nontreated. Three\u2010year risk of all\u2010cause mortality and new\u2010onset AF was assessed using adjusted Cox regression analyses. At discharge, 83\u00a0291 (73.9%) patients received\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition.\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition was associated with lower 3\u2010year risk of all\u2010cause mortality in\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              patients with AF, adjusted hazard ratio (\n              <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n              ) with 95% CI 0.75 (0.70\u20130.81),\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              patients without AF,\n              <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n              0.65 (0.60\u20130.69), AF patients without\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              ,\n              <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n              0.82 (0.75\u20130.90), and in patients without\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              and AF,\n              <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n              0.76 (0.72\u20130.81), respectively.\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition was not associated with lower 3\u2010year risk of new\u2010onset AF in patients without AF but with\/without\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              ;\n              <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>\n              0.96 (0.84\u20131.10) and 1.12 (1.02\u20131.22), respectively.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition post\u2010AMI was associated with lower risk of all\u2010cause mortality. In patients with\/without\n              <jats:styled-content style=\"fixed-case\">CHF<\/jats:styled-content>\n              ,\n              <jats:styled-content style=\"fixed-case\">RAS<\/jats:styled-content>\n              inhibition was not associated with lower incidence of new\u2010onset AF.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.116.005165","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:10:37Z","timestamp":1490055037000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Angiotensin\u2010Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Are Associated With Improved Outcome but Do Not Prevent New\u2010Onset Atrial Fibrillation After Acute Myocardial Infarction"],"prefix":"10.1161","volume":"6","author":[{"given":"Gorav","family":"Batra","sequence":"first","affiliation":[{"name":"Uppsala Clinical Research Center Uppsala Sweden"},{"name":"Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindhagen","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Andell","sequence":"additional","affiliation":[{"name":"Department of Cardiology Clinical Sciences Lund University Lund Sweden"},{"name":"Sk\u00e5ne University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology Clinical Sciences Lund University Lund Sweden"},{"name":"Sk\u00e5ne University Hospital Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center Uppsala Sweden"},{"name":"Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Spaak","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Danderyd University Hospital Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"Uppsala Clinical Research Center Uppsala Sweden"},{"name":"Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_3_2_3_2","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators . Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821\u2013828.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09374-X"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032292"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.555"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/23.10.882"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1686"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01185.2005"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.02.009"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.019"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs215"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.198804"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3457"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4067"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02212-1"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90865-X"},{"key":"e_1_3_2_24_2","first-page":"1115","article-title":"GISSI\u20103: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6\u2010week mortality and ventricular function after acute myocardial infarction","volume":"343","author":"Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico","year":"1994","unstructured":"Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto Miocardico . GISSI\u20103: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6\u2010week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115\u20131122.","journal-title":"Lancet"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.12.2643"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.7.1513"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00736-1"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)01044-5"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.050"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200001203420301"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14286-9"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042739"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69201-5"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072793.81076.D4"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.09.033"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.06.036"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.111.965178"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008816"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.4.376"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/heart.86.5.527"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.01.043"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.04.062"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.116.005165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:25:55Z","timestamp":1715595955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.005165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1161\/JAHA.116.005165"],"URL":"https:\/\/doi.org\/10.1161\/jaha.116.005165","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"2016-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-01-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e005165"}}